Related Experiment Video
Updated: Jun 15, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
[The management in chronic kidney disease (CKD)]
Mihaela Busuioc1, P Gusbeth-Tatomir, A Covic
1Facultatea de Medicină, Universitatea de Medicină si Farmacie Gr.T. Popa Iaşi.
This review explores experimental therapies targeting renal fibrosis, the main driver of chronic kidney disease (CKD) progression to end-stage renal disease (ESRD). Strategies aim to prevent or reverse kidney remodeling processes that cause fibrosis.
Area of Science:
- Nephrology
- Pathophysiology
- Translational Medicine
Context:
- Renal fibrosis is the primary mechanism driving chronic kidney disease (CKD) towards end-stage renal disease (ESRD).
- This process involves glomerulosclerosis, tubulointerstitial fibrosis, and vascular changes in the kidneys.
Purpose:
- To review and explore potential experimental therapeutic strategies for combating renal fibrosis.
- To investigate methods for preventing or reversing the pathological kidney remodeling that leads to fibrosis.
Summary:
- Tubulointerstitial injury, induced by oxidative stress, initiates cellular responses including tubular epithelial cell (TEC) apoptosis and fibroblast activation.
- Key fibrotic mechanisms include myofibroblast differentiation, immune cell proliferation (macrophages, fibrocytes), and epithelial-to-mesenchymal transition (EMT) of TECs.
Impact:
- Identifying novel therapeutic targets to halt or reverse kidney fibrosis.
- Potentially improving outcomes for patients with chronic kidney disease and preventing progression to ESRD.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
